Dyadic partners with MGH VIC and Voltron for vaccine antigens; part of $5.88M DoD award

DYADIC INTERNATIONAL INC

Dyadic’s C1 platform to express vaccine antigens for influenza A and other infectious diseases.
Collaboration stems from a $5.88M DoD award to VIC for Self-Assembling Vaccine platform.
Aims to enable scalable, rapid vaccine production in 100 days or less at flexible scales.
Potential commercial revenue for Dyadic if products are brought to market.
Partners include Vaccine and Immunotherapy Center at MGH and Voltron Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.